View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2025-results-302368325.html ...

2019年1月， Bio-Techne 正式发布了细胞和基因治疗全产品线方案。作为业内重要的GMP级原辅试剂和仪器供应商，Bio-Techne的解决方案可渗透入细胞和基因治疗的各个阶段：从早期的科研发现、细胞治疗生产工艺优化到最终的工业生产。 Bio-Techne秉持博采众方的精神 ...

Bio-Techne公司近日宣布，它以RNAscope™技术为基础，推出了RNA和蛋白质的共检测产品。 了解RNAscope技术及其在多个领域的应用>> Bio-Techne公司近日宣布，它以RNAscope™技术为基础，推出了RNA和蛋白质的共检测产品。RNAscope技术由Bio-Techne旗下品牌ACD开发，是一种先进的 ...

Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...

--Bio-Techne Corporation today reported its financial results for the third quarter ending March 31, 2025. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago. Improved pharma end market ...

The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Argus Research on November 20, 2025. The analyst firm set a price target for $68.00 expecting TECH to rise to within 12 months (a ...

Bio-Techne said yesterday it has agreed to acquire CyVek in a deal that could be worth up to $195 million depending on how milestones shake out over the next six years. The acquisition is Bio-Techne’s ...